A Case of a Cavitary Iris Melanoma with Aqueous Cytological Modulation.

Iris cyst Iris melanoma Uveal melanoma

Journal

Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 01 08 2018
accepted: 05 09 2018
entrez: 4 5 2019
pubmed: 3 5 2019
medline: 3 5 2019
Statut: ppublish

Résumé

Malignant melanoma is the most common primary malignant tumour of the iris, but represents a small proportion of all uveal melanomas. The authors describe a 34-year-old male with a pigmented lesion of the iris. The lesion remained stable for 7 years, but the patient re-presented after this time with sudden enlargement of the mass and hyphaema. Excisional biopsy confirmed cavitary melanoma of the iris. This is the first reported case of cavitation in a primary iris melanoma. The patient has not had any further adjuvant treatment and remains metastasis free at 5 years of follow-up.

Identifiants

pubmed: 31049323
doi: 10.1159/000493529
pii: oop-0005-0171
pmc: PMC6489039
doi:

Types de publication

Journal Article

Langues

eng

Pagination

171-175

Références

Trans Am Ophthalmol Soc. 1952;50:347-58
pubmed: 13102566
Arch Ophthalmol. 2005 Apr;123(4):569-71
pubmed: 15824238
Can J Ophthalmol. 2005 Oct;40(5):619-22
pubmed: 16391628
Cornea. 2006 Aug;25(7):863-5
pubmed: 17068469
Am J Ophthalmol. 1948 Feb;31(2):159-67
pubmed: 18905671
Br J Ophthalmol. 2009 Apr;93(4):535-40
pubmed: 19019926
Semin Ophthalmol. 2011 Jan;26(1):11-22
pubmed: 21275599
Oman J Ophthalmol. 2013 Jan;6(1):48-50
pubmed: 23772126
Biomed Pharmacother. 2017 Feb;86:502-513
pubmed: 28012930
Arch Ophthalmol. 1986 May;104(5):753-5
pubmed: 3707416
Arch Ophthalmol. 1982 Jan;100(1):112-4
pubmed: 7055461
Trans Am Ophthalmol Soc. 1996;94:259-71; discussion 271-4
pubmed: 8981700
Am J Ophthalmol. 1997 Feb;123(2):269-71
pubmed: 9186143
Ophthalmology. 1998 Jun;105(6):1091-8
pubmed: 9627662
Ophthalmology. 1998 Oct;105(10):1879-85
pubmed: 9787358

Auteurs

Lindsay A McGrath (LA)

Sheffield Ocular Oncology Service, Royal Hallamshire Hospital, Sheffield, United Kingdom.

James F Bacon (JF)

Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.

Paul Rundle (P)

Sheffield Ocular Oncology Service, Royal Hallamshire Hospital, Sheffield, United Kingdom.

Ian G Rennie (IG)

Sheffield Ocular Oncology Service, Royal Hallamshire Hospital, Sheffield, United Kingdom.

Hardeep Singh Mudhar (HS)

National Specialist Ophthalmic Pathology Service (NSOPS), Department of Histopathology, Royal Hallamshire Hospital, Sheffield, United Kingdom.

Classifications MeSH